Drug research

Taletrectinib

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as AB-106; DS-6051b

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLCNCT04919811	NUVB	Phase 2	Active not recruiting	2025-06-11Actual
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer PatientsNCT06564324	NUVB	Phase 3	Recruiting	2029-01Estimated
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)NCT07154706	NUVB	Phase 3	Recruiting	2030-08-30Estimated

NUVBActive not recruitingPrimary completion: 2025-06-11 · Actual

Trial details

NUVBRecruitingPrimary completion: 2029-01 · Estimated

Trial details

NUVBRecruitingPrimary completion: 2030-08-30 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.